Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 12,226 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Aging, Hiv, Loneliness, Social Isolation
Interventions: Village Model implementation; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: San Diego, California

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Ocrelizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis
Interventions: Interference onset; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Diabetes, Type I
Interventions: Technosphere Insulin, Active comparator; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 589 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more

Conditions: Congenital Hyperinsulinism
Interventions: RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4; Drug
Lead sponsor: Rezolute; Other
Eligibility: 2 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Fort Worth, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg; Drug
Lead sponsor: Metabolic Solutions Development Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Los Angeles, California • Miami Gardens, Florida • West Palm Beach, Florida + 5 more

Conditions: Opioid Dependency
Interventions: Probuphine (buprenorphine implant); Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Schizophrenia, Bipolar Disorder
Interventions: SAPHRIS, Asenapine; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 7
States / cities: Little Rock, Arkansas • Costa Mesa, California • Garden Grove, California + 4 more

Conditions: Healthy Volunteers
Interventions: AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: Crohn's Disease
Interventions: Azathioprine weight-based dose, Azathioprine individualised dose; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 10 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 12
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Multiple Myeloma
Interventions: BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more

Conditions: Plasma Cell Myeloma
Interventions: isatuximab SAR650984, carfilzomib, dexamethasone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: San Francisco, California • Spartanburg, South Carolina

Conditions: Autism, Gastro Intestinal Diseases
Interventions: Not listed
Lead sponsor: The Center for Discovery; Other
Eligibility: 5 Years to 19 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Harris, New York

Conditions: Mesial Temporal Lobe Epilepsy
Interventions: AAV9-hSyn1-miGRIK2; Genetic
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more

Conditions: Endometrial Hyperplasia
Interventions: BAY865028, Medroxyprogesterone acetate; Combination Product · Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more

Conditions: Chronic Graft-versus-host Disease
Interventions: Alefacept; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Boston, Massachusetts • Seattle, Washington • Milwaukee, Wisconsin

Conditions: Age-Related Macular Degeneration
Interventions: Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery; Biological · Drug · Procedure
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 779 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Interventions: CTX-471, Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more

Conditions: Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
Interventions: Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetic Foot Ulcer
Interventions: TWO2 Device, Placebo Device; Device
Lead sponsor: AOTI Ltd.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Phoenix, Arizona • Vacaville, California • Washington D.C., District of Columbia + 6 more

Conditions: Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions: IDOV-Immune (oncolytic vaccinia virus); Biological
Lead sponsor: ViroMissile, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: St Louis, Missouri • Houston, Texas • San Antonio, Texas

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more

Search by objective public record fields.

2nd AC+: New Village Model

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Ocrelizumab in Breastmilk

Consolidation & Interference in Multiple Sclerosis

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

Study of Probuphine in Patients With Opioid Dependence

Bio-equivalence Study Between SAPHRIS and Asenapine

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

Imuran Dosing in Crohn's Disease Study

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Identifying Biomarkers of Gastro Intestinal Comorbidities in Autism Spectrum Disorder

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

Effectiveness of Ofatumumab in Real-world Practice

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers

IDOV-Immune for Advanced Solid Tumors

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis